Indian biotechnology company Bharat Biotech has repurposed its Chiron Behring manufacturing plant in Ankleshwar, Gujarat, to scale up production of its anti-Covid vaccine, Covaxin, said people familiar with the development. In 2019, Bharat Biotech acquired it from pharmaceutical major Glaxo Smithkline. Apart from the Gujarat facility, Bharat Biotech has also refurbished its Malur plant in Karnataka to produce Covaxin doses to scale up production. According to Bharat Biotech, each batch of Covaxin undergoes over 200 quality control tests before being submitted to Central Drugs Laboratory for testing. The company has so far supplied at least 70 million doses for the national immunisation programme.

Source: Hindustan Times August 11, 2021 19:07 UTC